depression

Relmada discontinues late-stage trials for depression drug, explores sale
MSN/Reuters
Mon, 12/9/24 - 09:01 pm
Relmada Therapeutcs
depression
clinical trials
esmethadon
Can the girl power of Arrivo’s depression drug help reverse its fortunes?
Pharma Voice
Tue, 12/3/24 - 10:38 am
Arrivo
depression
gender
clinical trials
SP-624
Women's Health
Orexo exits depression DTx alliance with GAIA
Pharmaphorum
Mon, 12/2/24 - 10:18 am
Orexo
GAIA
digital therapeutics
DTx
depression
Spravato is just the beginning in a new wave of depression meds
Pharma Voice
Mon, 11/11/24 - 11:26 am
JNJ
Spravato
depression
drug development
Compass veers off course, delaying phase 3 psychedelic data and laying off 30% of staff
Fierce Biotech
Thu, 10/31/24 - 09:18 am
COMPASS Pathways
clinical trials
psychedelic drugs
depression
Australian biotech's cortisol blocker fails to improve attention in phase 2 depression study
Fierce Biotech
Mon, 08/12/24 - 11:31 am
Actinogen
cortisol blockers
depression
Alzheimer's disease
clinical trials
Autobahn’s road to a breakthrough depression treatment is paved with high-profile investors
Pharma Voice
Wed, 08/7/24 - 11:22 am
Autobahn Therapeutics
depression
ABX-002
major depressive disorder
J&J seeks expanded approval for antidepressant Spravato
BioPharma Dive
Mon, 07/22/24 - 06:43 pm
JNJ
depression
Spravato
MindBio’s LSD-based drug reduced depression symptoms in Phase IIa trial
Clinical Trials Arena
Thu, 06/20/24 - 11:32 am
MindBio Therapeutics
clinical trials
LSD
depression
MB22001
Karuna's captains set sail in new neuropsychiatric venture called Seaport Therapeutics
Fierce Biotech
Tue, 04/9/24 - 11:43 am
Karuna Therapeutics
Seaport Therapeutics
PureTech Health
funding
anxiety
depression
Engrail closes $157M series B, fueled by investors' renewed interest in neuropsychiatry
Fierce Biotech
Tue, 03/19/24 - 11:58 am
Engrail Therapeutics
funding
neuropsychiatric
anxiety
depression
New weight-loss drugs linked to lower risk of depression: study
Axios
Fri, 02/9/24 - 11:12 am
depression
weight loss
Novo Nordisk
Eli Lilly
Ozempic
Wegovy
Mounjaro
Alto Neuroscience preps IPO to push precision psychiatry therapies through the clinic
Fierce Biotech
Tue, 01/16/24 - 09:54 am
Alto Neuroscience
machine learning
artificial intelligence
IPOs
depression
J&J’s Spravato Bests Quetiapine in Phase III Head-to-Head Depression Study
BioSpace
Thu, 10/5/23 - 10:14 am
JNJ
clinical trials
Spravato
treatment-resistant depression
depression
Quetiapine
Exxua Charts a New Path in Depression Treatment Following FDA Nod
Xtalks
Thu, 09/28/23 - 11:38 pm
Fabre-Kramer Pharmaceuticals
FDA
Exxua
major depressive disorder
depression
Neumora, a richly funded brain drug developer, readies for an IPO
BioPharma Dive
Sun, 08/27/23 - 04:27 pm
Neumora Therapeutics
IPOs
depression
navacaprant
Brii Biosciences aims to come up big where Sage and Biogen fell short
Pharma Voice
Mon, 08/21/23 - 06:53 pm
Brii Biosciences
depression
SAGE Therapeutics
Biogen
BRII-296
postpartum depression
The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
BioSpace
Mon, 08/14/23 - 11:23 am
depression
Biogen
SAGE Therapeutics
zuranolone
Intra-Cellular Therapies
lumateperone
Alto Neuroscience
ALTO-100
schizophrenia
Karuna Therapeutics
KarXT
Cerevel Therapeutics
emraclidine
Acadia Pharmaceuticals
pimavanserin
Axesome Therapeutics
AXS-05
Alzheimer's agitation
NRx
NRX-101
bipolar disorder
Biohaven
troriluzole
OCD
VistaGen
fasedienol
social anxiety
Sage Stock Drops Despite Promising Phase III Depression Data
BioSpace
Thu, 07/27/23 - 11:30 am
SAGE Therapeutics
zuranolone
Biogen
depression
Relmada, reeling from 2 late-phase flops, plots comeback for depression drug
Fierce Biotech
Fri, 03/24/23 - 10:02 am
Relmada Therapeutics
clinical trials
depression
REL-1017

Pages